Products
Cirevetmab Biosimilar Canine Monoclonal Antibody (Canine TGF-β1) for Research
Cat No.: GMP-Bios-INN-1135
Anti-TGFB1 (Canine) therapeutic antibody (Pre-made Cirevetmab biosimilar,Canine Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cirevetmab (development code ZTS-00521426) is a canine monoclonal antibody targeting canine TGF-beta1. It is developed by Zoetis for chronic kidney disease.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1135-1mg | 1mg | 3090 |
| GMP-Bios-INN-1135-10mg | 10mg | |
| GMP-Bios-INN-1135-100mg | 100mg | |
| GMP-Bios-INN-1135-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Cirevetmab biosimilar, Canine Whole mAb, Anti-TGFB1 (Canine) Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody |
| INN Name | Cirevetmab |
| Target | TGFB1 (Canine) |
| Format | Canine Whole mAb |
| Derivation | Caninized |
| Species Reactivity | Canine |
| CH1+2+3 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Zoetis |
| Conditions Approved | na |
| Conditions Active | Chronic kidney disease |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
